We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Cencora (COR - Free Report) to post quarterly earnings of $4.37 per share in its upcoming report, which indicates a year-over-year increase of 9.3%. Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Cencora metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total U.S. Healthcare Solutions' at $75.00 billion. The estimate suggests a change of +2.9% year over year.
Analysts' assessment points toward 'Revenue- Total International Healthcare Solutions' reaching $7.79 billion. The estimate points to a change of 0% from the year-ago quarter.
The consensus estimate for 'Operating income- International Healthcare Solutions' stands at $158.45 million. Compared to the current estimate, the company reported $156.22 million in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Operating income- U.S. Healthcare Solutions' will likely reach $940.87 million. Compared to the present estimate, the company reported $901.79 million in the same quarter last year.
Shares of Cencora have experienced a change of +5.3% in the past month compared to the -0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), COR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect Cencora (COR - Free Report) to post quarterly earnings of $4.37 per share in its upcoming report, which indicates a year-over-year increase of 9.3%. Revenues are expected to be $84.89 billion, up 5.2% from the year-ago quarter.
Over the last 30 days, there has been an upward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Cencora metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Revenue- Total U.S. Healthcare Solutions' at $75.00 billion. The estimate suggests a change of +2.9% year over year.
Analysts' assessment points toward 'Revenue- Total International Healthcare Solutions' reaching $7.79 billion. The estimate points to a change of 0% from the year-ago quarter.
The consensus estimate for 'Operating income- International Healthcare Solutions' stands at $158.45 million. Compared to the current estimate, the company reported $156.22 million in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Operating income- U.S. Healthcare Solutions' will likely reach $940.87 million. Compared to the present estimate, the company reported $901.79 million in the same quarter last year.
View all Key Company Metrics for Cencora here>>>Shares of Cencora have experienced a change of +5.3% in the past month compared to the -0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), COR is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .